Molecular Nevogenesis
Author(s) -
Andrew L. Ross,
Margaret I. Sanchez,
James M. Grichnik
Publication year - 2011
Publication title -
dermatology research and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 29
eISSN - 1687-6113
pISSN - 1687-6105
DOI - 10.1155/2011/463184
Subject(s) - hras , neuroblastoma ras viral oncogene homolog , gnaq , mutation , melanoma , cancer research , nevus , biology , medicine , genetics , gene , kras
Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and GNAQ have been identified in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi, respectively. These mutations are likely to play a critical role in driving nevogenesis. While each mutation is able to activate the MAP kinase pathway, they also interact with a host of different proteins in other pathways. The different melanocytic developmental pathways activated by each mutation cause the cells to migrate, proliferate, and differentiate to different extents within the skin. This causes each mutation to give rise to a characteristic growth pattern. The exact location and differentiation state of the cell of origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that most of the same developmental pathways are also present in melanoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom